Nuvalent (NUVL) Research & Development (2020 - 2026)
Nuvalent (NUVL) posted Research & Development of $83.6 million for Q1 2026, up 23.32% on a QoQ basis from $67.8 million in Q4 2025, and up 12.35% year-over-year from $74.4 million in Q1 2025.
Nuvalent (NUVL) Research & Development (2020 - 2026) Analysis & Trends
Nuvalent's Research & Development history runs 7 years deep, the most recent figure standing at $83.6 million for Q1 2026.
- Quarterly Research & Development rose 12.35% year-over-year to $83.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $316.2 million (up 24.69% YoY) and the FY2025 annual result came in at $307.0 million, up 40.96% from the prior year.
- Research & Development was $83.6 million for Q1 2026 at Nuvalent, up from $67.8 million in the prior quarter.
- Across five years, Research & Development topped out at $83.8 million in Q3 2025 and bottomed at $12.7 million in Q1 2022.
- A 5-year average of $46.2 million and a median of $38.6 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development soared 131.46% — and 2025, when it declined 2.34%.
- Nuvalent's Research & Development stood at $22.9 million in 2022, then soared by 55.7% to $35.6 million in 2023, then surged by 95.09% to $69.4 million in 2024, then slipped by 2.34% to $67.8 million in 2025, then climbed by 23.32% to $83.6 million in 2026.
- Business Quant data shows NUVL's Research & Development at $83.6 million in Q1 2026, $67.8 million in Q4 2025, and $83.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | 83.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 83.61 Mn |
| Dec 31, 2025 | 67.80 Mn |
| Sep 30, 2025 | 83.84 Mn |
| Jun 30, 2025 | 80.91 Mn |
| Mar 31, 2025 | 74.42 Mn |
| Dec 31, 2024 | 69.42 Mn |
| Sep 30, 2024 | 60.55 Mn |
| Jun 30, 2024 | 49.17 Mn |
| Mar 31, 2024 | 38.63 Mn |
| Dec 31, 2023 | 35.59 Mn |
| Sep 30, 2023 | 29.61 Mn |
| Jun 30, 2023 | 25.92 Mn |
| Mar 31, 2023 | 22.13 Mn |
| Dec 31, 2022 | 22.86 Mn |
| Sep 30, 2022 | 14.63 Mn |
| Jun 30, 2022 | 13.56 Mn |
| Mar 31, 2022 | 12.69 Mn |
| Dec 31, 2021 | 13.19 Mn |
| Sep 30, 2021 | 9.06 Mn |
| Jun 30, 2021 | 7.83 Mn |